Astria Therapeutics chooses Ypsomed’s YpsoMate as the injection device for STAR-0215 for the treatment of hereditary angioedema

Astra Therapeutics announced that it has chosen Ypsomed as its partner for the development of an autoinjector for STAR-0215.

John Ruesch, Senior Vice President, Pharmaceutical Sciences and Technical Operations at Astria, said: “With STAR-0215’s profile, our goal is to develop a therapy that allows patients to choose an approach that works best for their lives with the option of infrequent three- and six-month administration. Our partnership with Ypsomed, a leading developer and manufacturer of injection systems, supports this goal through the planned development of an autoinjector that enables our vision for STAR-0215 to be a therapy that can effectively protect against HAE attacks while also having a very low burden of treatment and administration.”

Assuming regulatory approval, Astria plans to launch STAR-0215 with both the Ypsomed YpsoMate autoinjector and a pre-filled syringe, which would allow patients to choose the administration regimen that would work best for their lives. Astria believes that an autoinjector option is a great choice for STAR-0215 due to its ease of use, needle shielding feature, and STAR-0215’s proprietary formulation that enables a quick injection with low risk of pain.

The YpsoMate is a user-friendly two-step autoinjector. To inject, the cap is removed and then the device is firmly pushed on the patient’s skin. Visual and audible cues notify the patient of the start and end of the injection, and the needle is covered before and after the injection by a safety mechanism that protects against needle-stick injuries and ensures that patients do not see the needle. Furthermore, the autoinjector is based on Ypsomed’s carbon footprint reduction NetZero Program, which reflects a company-wide commitment to sustainability.

(Source: Astria)